FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044262802> ?p ?o ?g. }

• W2044262802 abstract "Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DCRationale Aggressive fibromatosis (AF) is a rare fibroblastic proliferative neoplasm with locally malignant behaviour which never metastasises. Systemic treatment active in relapsing or non resectable AF include NSAIDs, antioestrogens, chemotherapy, imatinib. This study was conducted to define the predictive and prognostic value of miRNA expression profile for relapsing AF receiving imatinib for 1 year within the Desminib trial (Penel et al., Ann Oncol, 2011). Material and methods 500 ng of RNA were extracted from FFPE tissues samples of patients included in the Desminib trial: 26 of 40 patients had sufficient quantity material. The expression of 384 miRNAs for each patient was analysed using a microfluidic platform (Applied Biosystems.). Supervised and unsupervised hierarchical clustering were performed. Supervised analysis compared 1) progressive vs non progressive patients under treatment, 2) patients non progressing during imatinib but progressing within 2 years after imatinib interruption vs never progressive patients. Anova method was used to identify the statistically significant miRNAs, discriminants between the 2 groups (with p value < 0.05). These miRNAs were included into the “Kyoto Encyclopedia of Genes and Genome”. Results 1) Predictive value: the expression of the 4 following miRNA was found to differ significantly between patients progressing or not during imatinib:. Wnt pathway is impacted by these miRNAs (which induces Wnt and Fz) as well as as cKIT and PDGFR, known targets of imatinib. 2) Prognostic value Among 20 patients non progressing while imatinib, 29 miRNA had a significant differential expression in progressive (n=5) vs non progressive patients (n=8) during the follow-up (7 patients had a nonsufficient follow up). 19 miR were identified as highly discriminant with a p-value ranging from 7.73.10−5 to 9.8.10−3. All these miRNA were under expressed in progressive patients. Wnt pathway is largely targeted by these miRNAs (which induces Wnt, Fz, GSK-3β, axin, APC, TCF/LEF and cyclin D1). The unsupervised hierarchical clustering of the 26 patients identified 2 groups of thirteen patients each. Median TTP in each group is 27.4 and 33.8 months, respectively. Anova study of this clustering identified 12 discriminant miRNAs, whose 9 miRNAs with p-value ranging from 6.51.10−8 to 1.24.10−4, also identified by Anova of the prognostic supervised clustering. Conclusion These results bring the first demonstration of predictive and prognostic value of miRNA expression profile in AF treated with imatinib. The next objective is 1) to confirm these results in a prospective cohort and 2) to precisely identify a miRNA signature to select patients with a non progressive disease in whom surgical resection of the primary tumor could be spared.Citation Format: Armelle Dufresne, Marie Paturel, Nicolas Penel, Axel Le Cesne, Binh Bui, Daniel Pissaloux, Laurent Alberti, Jean Yves Blay. Predictive and prognostic value of miRNA expression profile in aggressive fibromatosis treated with imatinib. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1965. doi:10.1158/1538-7445.AM2013-1965" @default.
• W2044262802 created "2016-06-24" @default.
• W2044262802 creator A5001102421 @default.
• W2044262802 creator A5006945230 @default.
• W2044262802 creator A5047925931 @default.
• W2044262802 creator A5052242950 @default.
• W2044262802 creator A5076690638 @default.
• W2044262802 creator A5084291360 @default.
• W2044262802 creator A5085936617 @default.
• W2044262802 creator A5089424512 @default.
• W2044262802 date "2013-04-15" @default.
• W2044262802 modified "2023-09-27" @default.
• W2044262802 title "Abstract 1965: Predictive and prognostic value of miRNA expression profile in aggressive fibromatosis treated with imatinib." @default.
• W2044262802 doi "https://doi.org/10.1158/1538-7445.am2013-1965" @default.
• W2044262802 hasPublicationYear "2013" @default.
• W2044262802 type Work @default.
• W2044262802 sameAs 2044262802 @default.
• W2044262802 citedByCount "0" @default.
• W2044262802 crossrefType "proceedings-article" @default.
• W2044262802 hasAuthorship W2044262802A5001102421 @default.
• W2044262802 hasAuthorship W2044262802A5006945230 @default.
• W2044262802 hasAuthorship W2044262802A5047925931 @default.
• W2044262802 hasAuthorship W2044262802A5052242950 @default.
• W2044262802 hasAuthorship W2044262802A5076690638 @default.
• W2044262802 hasAuthorship W2044262802A5084291360 @default.
• W2044262802 hasAuthorship W2044262802A5085936617 @default.
• W2044262802 hasAuthorship W2044262802A5089424512 @default.
• W2044262802 hasConcept C104317684 @default.
• W2044262802 hasConcept C121608353 @default.
• W2044262802 hasConcept C126322002 @default.
• W2044262802 hasConcept C137620995 @default.
• W2044262802 hasConcept C142724271 @default.
• W2044262802 hasConcept C143998085 @default.
• W2044262802 hasConcept C145059251 @default.
• W2044262802 hasConcept C2775983998 @default.
• W2044262802 hasConcept C2777583451 @default.
• W2044262802 hasConcept C2778729363 @default.
• W2044262802 hasConcept C502942594 @default.
• W2044262802 hasConcept C55493867 @default.
• W2044262802 hasConcept C71924100 @default.
• W2044262802 hasConcept C86803240 @default.
• W2044262802 hasConceptScore W2044262802C104317684 @default.
• W2044262802 hasConceptScore W2044262802C121608353 @default.
• W2044262802 hasConceptScore W2044262802C126322002 @default.
• W2044262802 hasConceptScore W2044262802C137620995 @default.
• W2044262802 hasConceptScore W2044262802C142724271 @default.
• W2044262802 hasConceptScore W2044262802C143998085 @default.
• W2044262802 hasConceptScore W2044262802C145059251 @default.
• W2044262802 hasConceptScore W2044262802C2775983998 @default.
• W2044262802 hasConceptScore W2044262802C2777583451 @default.
• W2044262802 hasConceptScore W2044262802C2778729363 @default.
• W2044262802 hasConceptScore W2044262802C502942594 @default.
• W2044262802 hasConceptScore W2044262802C55493867 @default.
• W2044262802 hasConceptScore W2044262802C71924100 @default.
• W2044262802 hasConceptScore W2044262802C86803240 @default.
• W2044262802 hasLocation W20442628021 @default.
• W2044262802 hasOpenAccess W2044262802 @default.
• W2044262802 hasPrimaryLocation W20442628021 @default.
• W2044262802 hasRelatedWork W1538393364 @default.
• W2044262802 hasRelatedWork W1570168615 @default.
• W2044262802 hasRelatedWork W1971488125 @default.
• W2044262802 hasRelatedWork W2025873758 @default.
• W2044262802 hasRelatedWork W2032312263 @default.
• W2044262802 hasRelatedWork W2108104027 @default.
• W2044262802 hasRelatedWork W2152032358 @default.
• W2044262802 hasRelatedWork W2323501164 @default.
• W2044262802 hasRelatedWork W2333037897 @default.
• W2044262802 hasRelatedWork W2340777518 @default.
• W2044262802 hasRelatedWork W2374279538 @default.
• W2044262802 hasRelatedWork W2439955832 @default.
• W2044262802 hasRelatedWork W2463178543 @default.
• W2044262802 hasRelatedWork W2550214257 @default.
• W2044262802 hasRelatedWork W2564993053 @default.
• W2044262802 hasRelatedWork W2740835204 @default.
• W2044262802 hasRelatedWork W2887479062 @default.
• W2044262802 hasRelatedWork W2954908343 @default.
• W2044262802 hasRelatedWork W2955095650 @default.
• W2044262802 hasRelatedWork W3000239856 @default.
• W2044262802 isParatext "false" @default.
• W2044262802 isRetracted "false" @default.
• W2044262802 magId "2044262802" @default.
• W2044262802 workType "article" @default.